CTOs on the Move

Quantom Genomics

www.quantum-genomics.com

 
Quantum Genomics is a biopharmaceutical company specializing in the development of a new drug class for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Sss Co

Sss Co is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arrakis Therapeutics

Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Massachusetts.

Aoxing Pharmaceutical

Aoxing Pharmaceutical Company, Inc (NYSE AMEX: AXN) is registered in Florida in US and it is a specialty pharmaceutical company which specializes in research, development, manufacturing and distribution of a variety of narcotics and pain-management products and drug-relief medicine. Aoxing has its office in Jersey city and headquartered in Shijiazhuang City, outside Beijing, Aoxing has the largest and most advanced manufacturing facility for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration (SFDA). It has strategic alliance partnerships with Johnson Matthey Plc (LSE: JMAT), QRx Pharma (ASX: QRX) and American Oriental Bioengineering, Inc (NYSE: AOB).

Union Springs Pharmaceuticals

Union Springs Pharmaceuticals is a Union, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sagimet

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a platform of proprietary FASN inhibitors.